The SPRED1 gene encodes for a tumor suppressor protein, which inhibits the MAPK pathway by interacting with NF1; SPRED1 loss acts as a molecular driver in MM [41] and has been identified in less than 8% of MM patients, possibly representing a distinct biological entity [15]. Here, NF1 is linked to Miyoshi myopathy.